Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Kyverna Therapeutics' chief executive, Peter Maag, has resigned after less than two years at helm of the clinical-stage biopharmaceutical company. Kyverna on Monday said Warner Biddle, most recently ...

Warner Biddle and Christi Shaw, two prominent former executives at Gilead’s CAR-T division, will try to turn around an ...

The "Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and ...

Notable insider trades include Parsey Merdad, Chief Medical Officer at Gilead Sciences, Inc. (GILD), who sold 21246 shares on Sep 12 ’24, at $84.5 each, totaling $1.80 million. On Sep 12 ’24, Mercier ...

Warner Biddle has been appointed as CEO, Kyverna Therapeutics, following the resignation of Peter Maag this week.